Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®
Background: Trastuzumab-emtansine (T-DM1, commercial name: Kadcyla) is well-known antibody-drug conjugate (ADC) and was first approved for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This molecular format consisting of trastuzumab and maytansinoid payload (emta...
Збережено в:
| Автори: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
IMR Press
2022-08-01
|
| Серія: | Frontiers in Bioscience-Landmark |
| Предмети: | |
| Онлайн доступ: | https://www.imrpress.com/journal/FBL/27/8/10.31083/j.fbl2708234 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|